Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 7/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23474092 | 0.81 | LCK (0.41) | ALOX5APFEN1LMNAGABRA5MAPK1 | |
| SCHEMBL23474167 | 0.80 | LMNA (0.41) | ALOX5APFEN1LMNAGABRA5MAPK1 | |
| SCHEMBL24313798 | 0.78 | LIPE (0.43) | DGAT1LIPELMNAMAPK1 | |
| SCHEMBL1623079 | 0.74 | PTPN11 (0.47) | DGAT1LCK | |
| SCHEMBL29750908 | 0.74 | PTPN11 (0.47) | DGAT1LCK | |
| SCHEMBL15774244 | 0.73 | HDAC1 (0.44) | DGAT1LMNALCKKDM4E | |
| SCHEMBL31162850 | 0.73 | HDAC1 (0.44) | DGAT1LMNALCKKDM4E | |
| SCHEMBL3451006 | 0.72 | ALOX15 (0.44) | DGAT1CXCR2MAPK1KDM4EL3MBTL1 | |
| SCHEMBL15897022 | 0.70 | LIPG (0.57) | — | |
| SCHEMBL19808852 | 0.69 | SCN9A (0.48) | LMNAGABRA5MAPK1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO LTD (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO LTD (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20220388997-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD. (CN) | 2022-12-08 | — | — | US | disclosed |
| WO-2021109712-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD. (CN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021109713-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO., LTD. (CN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021108974-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD (CN) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | VIM, CYP3A7, HAVCR2 | DGAT1 3877/4885LIPE 3810/4885ALOX5AP 2940/4885 |
| US-20220388997-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | NR1H4, FXR1, FXR2 | DGAT1 431/4885LIPE 916/4885ALOX5AP 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.